|
|
|
Insider
Information: |
Schimmel Paul |
Relationship: |
Director |
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
1,717,702 |
|
Indirect Shares
|
1,312,785 |
|
|
Direct
Value |
$98,302,233 |
|
|
Indirect Value
|
$46,356,416 |
|
|
Total
Shares |
3,030,487 |
|
|
Total
Value |
$144,658,649 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Alnylam Pharmaceuticals Inc |
ALNY |
Director |
2018-03-13 |
0 |
2018-03-13 |
306,996 |
Premium* |
|
Repligen Corp |
RGEN |
Director |
2007-06-14 |
665,106 |
2005-11-07 |
0 |
Premium* |
|
Avicena Group, Inc. |
AVCE |
Director |
2006-12-28 |
1,020,242 |
2005-11-23 |
0 |
Premium* |
|
aTyr Pharma Inc |
LIFE |
Director |
2023-05-10 |
8,890 |
2023-05-10 |
992,166 |
Premium* |
|
Forte Biosciences Inc |
FBRX |
Director |
2017-04-19 |
23,464 |
2017-04-19 |
13,623 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 1
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
RGEN |
Repligen Corp |
Director |
|
2005-11-07 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,576 |
658,106 |
|
- |
|
RGEN |
Repligen Corp |
Director |
|
2006-08-11 |
4 |
OE |
$0.88 |
$4,400 |
D/D |
5,000 |
663,106 |
|
- |
|
RGEN |
Repligen Corp |
Director |
|
2007-02-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
660,106 |
0 |
- |
|
RGEN |
Repligen Corp |
Director |
|
2007-06-14 |
4 |
OE |
$1.00 |
$5,000 |
D/D |
5,000 |
665,106 |
0 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2015-05-06 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
12,572 |
|
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2015-05-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
129,995 |
|
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2015-05-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,429 |
|
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
547,353 |
646,167 |
0 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2015-09-16 |
4 |
GD |
$0.00 |
$0 |
I/I |
11,925 |
634,242 |
0 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-05 |
4 |
B |
$3.52 |
$88,118 |
D/D |
25,000 |
37,572 |
2.39 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-06 |
4 |
B |
$3.20 |
$80,000 |
D/D |
25,000 |
62,572 |
2.39 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-07 |
4 |
B |
$3.19 |
$127,584 |
D/D |
40,000 |
102,572 |
2.39 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-08 |
4 |
B |
$3.22 |
$273,649 |
D/D |
85,000 |
187,572 |
2.39 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-11 |
4 |
B |
$3.45 |
$116,535 |
D/D |
32,659 |
220,231 |
2.39 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-11 |
4/A |
B |
$3.45 |
$97,643 |
I/I |
27,400 |
233,581 |
2.1 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-11 |
4/A |
B |
$3.59 |
$18,891 |
D/D |
5,259 |
17,831 |
2.39 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-12 |
4 |
B |
$3.70 |
$24,220 |
I/I |
6,546 |
240,127 |
2.1 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-12 |
4 |
B |
$3.75 |
$9,682 |
D/D |
2,581 |
20,412 |
2.39 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-13 |
4 |
B |
$3.85 |
$37,865 |
I/I |
9,835 |
249,962 |
2.1 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-14 |
4 |
B |
$4.14 |
$135,075 |
D/D |
32,600 |
53,012 |
2.39 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-04-14 |
4 |
B |
$4.22 |
$141,859 |
I/I |
33,619 |
283,581 |
2.1 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-09-23 |
4 |
GA |
$0.00 |
$0 |
I/I |
12,572 |
646,814 |
0 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-09-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
12,572 |
40,440 |
0 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-12-15 |
4 |
B |
$2.50 |
$99,912 |
I/I |
40,000 |
686,814 |
2.1 |
- |
|
LIFE |
aTyr Pharma Inc |
Director |
|
2016-12-16 |
4 |
B |
$2.40 |
$23,973 |
I/I |
10,000 |
696,814 |
2.1 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|